Liquidia (LQDA) Stock Analysis & AI Equity Report
Liquidia (LQDA) overview
Liquidia (LQDA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 158m and operating profit of USD -51.4m; the year-end share price was 34.49 USD and market capitalisation was USD 3,008m. Liquidia is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Liquidia's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Liquidia
Liquidia develops and commercializes inhaled therapies for pulmonary and vascular diseases using its PRINT drug-particle technology. Its marketed product YUTREPIA is treprostinil inhalation powder approved for pulmonary arterial hypertension. The company is developing L606, an investigational extended-release treprostinil formulation for pulmonary hypertension, and studying YUTREPIA in additional conditions, including systemic sclerosis-associated Raynaud’s phenomenon.
Generate the Liquidia report
Liquidia is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Liquidia and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Liquidia
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.